Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
When compared head-to-head with semaglutide in the SURPASS 2 trial, nausea was reported in 1722% of patients who received tirzepatide, and in 18% who received semaglutide
You can take our free assessment quiz today to explore your options and see if a tirzepatide-based program is the right fit for your journey toward better health
It does not independently establish molecular identity, net peptide content, water content, counterion content, residual-solvent content, aggregate content, sterility, endotoxin status, or suitability for a biological application
At the same time, fiber intake often decreases as overall food intake becomes lower
The post hoc analysis, which included the four SURMOUNT trials [1], compared tirzepatide with a placebo for up to 72 to 88 weeks in 4,677 adults (2,999 females, 1,678 males) living with obesity, highlighting potential sex differences in the response
US$ 22.40
US$ 21.35
US$ 24.95
US$ 23.72
US$ 25.99
US$ 23.26
US$ 26.61
